Research on life quality in patients with nonalcoholic fatty liver diseases
TAO Ye-ting, YAN Shi-yan, CHEN Guang-yu, PAN Qin, CHEN Yuan-wen, FAN Jian-gao
2016, 21(12):
1017-1022.
Asbtract
(
209 )
PDF (956KB)
(
320
)
References |
Related Articles |
Metrics
Objective To discuss the association between nonalcoholic fatty liver disease (NAFLD) and health-related quality of life (HRQoL). Methods Three hundred and nineteen adults who had physical examinations and sixty-four patients with liver diseases except NAFLD (89.1% were chronic hepatitis B, CHB) were enrolled. Measurements of controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and serum transaminase were performed for NAFLD screening. HRQoL were assessed by short form health survey (SF-36). Results In NALFD group, scores of physical function (PF) (90.22±12.83), role-physical (RP) (84.41±28.05), general health (GH) (65.67±19.75) and vitality (VT) (75.00±15.69) were significantly lower than those in healthy control group (84.90±14.34, 75.63±34.20, 55.02±18.73 and 69.82±15.32, all P<0.05), but not obviously different from those in non-NALFD liver disease group (82.58±19.07, 56.64±43.47, 52.06±19.42 and 66.02±19.80, all P>0.05). There was a statistically significant decreasing tendency in PF (90.22±12.83 vs 83.41±15.25 vs 86.10±13.51), GH (65.67±19.75 vs 55.03±20.60 vs 55.00±17.16) and VT scores (75.00±15.69 vs 69.77±14.84 vs 69.86±15.76) from healthy control group to mild hepatic steatosis group, to moderate and severe hepatic steatosis group (all P<0.05). Additionally, PF (87.33±13.84 vs 86.40±15.58 vs 77.73±12.51), RP (79.27±32.18 vs 76.75±35.94 vs 60.23±37.53), body pain (BP) (80.31±20.01 vs 76.61±20.07 vs 66.59±25.01), GH (59.63±19.78 vs 55.61±20.40 vs 47.82±20.72) and VT scores (72.77±15.16 vs 70.96±15.60 vs 63.86±19.27) showed significantly downward trends from fibrosis-free group to fibrosis group, and to cirrhosis group (all P<0.05). In NAFLD patients, obesity group had significantly lower scores in VT (73.06±14.69 vs 68.33±15.42) and health transition (HT) (47.58±17.94 vs 41.11±20.59) than non-obesity group (P<0.05). Compared with normal aminotransferase group, elevated aminotransferase group had significantly lower scores in GH and VT (59.82±20.72 vs 52.84±18.59, 73.18±16.26 vs 68.36±14.59, all P<0.05). Conclusion Similar to non-NAFLD liver disease patients that mainly composed of CHB, NAFLD patients showed a severe impairment in HRQoL.